Trifluridine and Tipiracil

Brand names: Lonsurf ยท Active ingredient: Trifluridine, Tipiracil Hydrochloride

In short: LONSURF, as a single agent or in combination with bevacizumab, is indicated for the treatment of adult patients with metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-

Forms & strengthsTablets: 15 mg trifluridine/6.14 mg tipiracil: white, biconvex, round, film-coated, imprinted with โ€˜15โ€™ on one side, and โ€˜102โ€™ and โ€˜15 mgโ€™ on the other side, in gray ink. โ€ฆ
LabelTaiho Pharmaceutical Co., Ltd.
Label updatedNov 18, 2025

What is Trifluridine and Tipiracil used for?

LONSURF, as a single agent or in combination with bevacizumab, is indicated for the treatment of adult patients with metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.

LONSURF is indicated for the treatment of adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy.

Trifluridine and Tipiracil dosage

The recommended dosage of LONSURF as a single agent or in combination with bevacizumab is 35 mg/m2 up to a maximum of 80 mg per dose (based on the trifluridine component) orally twice daily with food on Days 1 through 5 and Days 8 through 12 of each 28-day cycle until disease progression or unacceptable toxicity. Round dose to the nearest 5 mg increment.

Refer to the Prescribing Information for bevacizumab dosing information.

Instruct patients to swallow LONSURF tablets whole.

Instruct patients not to retake doses of LONSURF that are vomited or missed and to continue with the next scheduled dose.

LONSURF is a cytotoxic drug. Follow applicable special handling and disposal procedures.1

Table 1 shows the calculated initial daily dose based on body surface area (BSA).

BSA(m2) | Total dailydose (mg) | Dose (mg)administeredtwice daily | Tablets per dose

15 mg | 20 mg

< 1.07 | 70 | 35 | 1 | 1

1.07 โ€“ 1.22 | 80 | 40 | 0 | 2

1.23 โ€“ 1.37 | 90 | 45 | 3 | 0

1.38 โ€“ 1.52 | 100 | 50 | 2 | 1

1.53 โ€“ 1.68 | 110 | 55 | 1 | 2

1.69 โ€“ 1.83 | 120 | 60 | 0 | 3

1.84 โ€“ 1.98 | 130 | 65 | 3 | 1

1.99 โ€“ 2.14 | 140 | 70 | 2 | 2

2.15 โ€“ 2.29 | 150 | 75 | 1 | 3

โ‰ฅ2.30 | 160 | 80 | 0 | 4

Obtain complete blood cell counts prior to and on Day 15 of each cycle .

Do not initiate the cycle of LONSURF until:

Absolute neutrophil count (ANC) greater than or equal to 1,500/mm3 or febrile neutropenia is resolved

Platelets greater than or equal to 75,000/mm3

Grade 3 or 4 non-hematological adverse reactions are resolved to Grade 0 or 1

Within a treatment cycle, withhold LONSURF for any of the following:

Absolute neutrophil count (ANC) less than 500/mm3 or febrile neutropenia

Platelets less than 50,000/mm3

Grade 3 or 4 non-hematologic adverse reaction

After recovery, resume LONSURF after reducing the dose by 5 mg/m2/dose from the previous dose, if the following occur:

Febrile neutropenia

Uncomplicated Grade 4 neutropenia (which has recovered to greater than or equal to 1,500/mm3) or thrombocytopenia (which has recovered to greater than or equal to 75,000/mm3) that results in more than 1 week delay in start of next cycle

Non-hematologic Grade 3 or Grade 4 adverse reaction except for Grade 3 nausea and/or vomiting controlled by antiemetic therapy or Grade 3 diarrhea responsive to antidiarrheal medication

A maximum of 3 dose reductions are permitted. Permanently discontinue LONSURF in patients who are unable to tolerate a dose of 20 mg/m2 orally twice daily. Do not escalate LONSURF dosage after it has been reduced.

Refer to the bevacizumab prescribing information for dose modifications for adverse reactions associated with bevacizumab. โ€ฆ

How to take Trifluridine and Tipiracil โ€” instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Severe Myelosuppression

Advise patients to immediately contact their healthcare provider if they experience signs or symptoms of infection and advise patients to keep all appointments for blood tests .

Gastrointestinal Toxicity

Advise patients to contact their healthcare provider for severe or persistent nausea, vomiting, diarrhea, or abdominal pain .

Administration Instructions

Advise patients that LONSURF is available in two strengths and they may receive both strength tablets to provide the prescribed dosage.

Advise patients to take LONSURF with food .

Advise patients not to retake doses of LONSURF that are vomited or missed and to continue with the next scheduled dose.

Advise patients that anyone else who handles their medication should wear gloves .

Embryo-Fetal Toxicity

Advise pregnant women and females of reproductive potential of the potential risk to the fetus. Advise females to inform their healthcare provider of a known or suspected pregnancy . โ€ฆ

Warnings & precautions

Do not take this medicine if: None.

In the 1114 patients who received LONSURF as a single agent, LONSURF caused severe or life-threatening myelosuppression (Grade 3-4) consisting of neutropenia (38%), anemia (17%), thrombocytopenia (4%) and febrile neutropenia (3%). Three patients (0.3%) died due to neutropenic infection/sepsis; four other patients (0.5%) died due to septic shock. A total of 14% of patients received granulocyte-colony stimulating factors.

In the 246 patients who received LONSURF in combination with bevacizumab, LONSURF caused severe or life-threatening myelosuppression (Grade 3-4) consisting of neutropenia (52%), anemia (5%), thrombocytopenia (4%) and febrile neutropenia (0.4%). One patient (0.4%) died due to abdominal sepsis and two other patients (0.8%) died due to septic shock. A total of 29% of patients received granulocyte-colony stimulating factors. Obtain complete blood counts prior to and on Day 15 of each cycle of LONSURF and more frequently as clinically indicated. Withhold LONSURF for severe myelosuppression and resume at the next lower dosage .

Based on animal studies and its mechanism of action, LONSURF can cause fetal harm when administered to a pregnant woman. Trifluridine/tipiracil caused embryo-fetal lethality and embryo-fetal toxicity in pregnant rats when orally administered during gestation at dosage levels resulting in exposures lower than those achieved at the recommended dosage of 35 mg/m2 twice daily. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use an effective method of contraception during treatment with LONSURF and for at least 6 months after the final dose .

Trifluridine and Tipiracil side effects

The following clinically significant adverse reactions are described elsewhere in the labeling:

Severe Myelosuppression

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The data described in the WARNINGS AND PRECAUTIONS section and below reflect exposure to LONSURF at the recommended dose in 533 patients with metastatic colorectal cancer in RECOURSE, 246 patients with metastatic colorectal cancer treated with LONSURF as monotherapy in SUNLIGHT and 335 patients with metastatic gastric cancer in TAGS. Among the 1114 patients who received LONSURF as a single agent, 12% were exposed for 6 months or longer and 1% were exposed for 12 months or longer. The most common adverse reactions or laboratory abnormalities (โ‰ฅ10%) were neutropenia, anemia, thrombocytopenia, fatigue, nausea, decreased appetite, diarrhea, vomiting, abdominal pain, and pyrexia.

Among the 246 patients with metastatic colorectal cancer treated with LONSURF in combination with bevacizumab in SUNLIGHT, 39% were exposed for 6 months or longer, and 14% were exposed for 12 months or longer. โ€ฆ

About this medicine

LONSURF contains trifluridine and tipiracil hydrochloride at a molar ratio of 1:0.5.

Trifluridine

Trifluridine, a nucleoside metabolic inhibitor, is described chemically as 2โ€™-deoxy-5-(trifluoromethyl) uridine and has the following structural formula:

Trifluridine has a molecular formula C10H11F3N2O5 and a molecular weight of 296.20. Trifluridine is a white crystalline powder, soluble in water, ethanol, 0.01 mol/L hydrochloric acid, 0.01 mol/L sodium hydroxide solution; freely soluble in methanol, acetone; sparingly soluble in 2-propanol, acetonitrile; slightly soluble in diethyl ether; and very slightly soluble in isopropyl ether.

Tipiracil hydrochloride

Tipiracil hydrochloride, a thymidine phosphorylase inhibitor, is described chemically as 5-chloro-6-[(2-iminopyrrolidin-1-yl)methyl]pyrimidine-2,4-(1H,3H)-dione monohydrochloride or 2,4(1H,3H)-Pyrimidinedione, 5-chloro-6-[(2-imino-1-pyrrolidinyl)methyl]-, hydrochloride (1:1) and has the following structural formula:

Tipiracil hydrochloride has a molecular formula C9H11ClN4O2โ€ขHCl and a molecular weight of 279.12. โ€ฆ

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label โ€” it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID f5beed22-d71d-4c0d-8dca-2c7317d65d85. Read the full official label on DailyMed.

Related medicines

Omeprazole Pantoprazole Fluoxetine Amoxicillin Famotidine Ondansetron Esomeprazole Docusate